相关实验视频

Updated: Mar 7, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

前列腺特异性膜抗原:分子功能和作为治疗点的新兴角色 (综述)

Ryuta Watanabe¹, Tomohisa Sakaue², Noriyoshi Miura¹

¹Department of Urology, Ehime University Hospital, Toon, Ehime 791‑0295, Japan.

Molecular medicine reports

|March 6, 2026

概括

前列腺特异性膜抗原 (PSMA) 是瘤生物学的关键调节者,影响瘤的增殖,新陈代谢和微观环境. 了解其分子功能对于开发有效的PSMA向疗法至关重要.

科学领域:

生物化学生物化学
分子生物学分子生物学
在瘤学瘤学.

背景情况:

前列腺特异性膜抗原 (PSMA) 从前列腺癌生物标志物演变为瘤生物学中的关键因素.
PSMA具有酶活性 (谷氨酸碳酸酶,叶酸酸酶) 并充当信号中心.
它的表达受到各种信号通路和表观遗传因素的调节.

研究的目的:

审查PSMA在成像和治疗中的临床应用之外的分子功能.
阐明PSMA在将新陈代谢与细胞增殖,氧化还原平衡和表观遗传学联系中的作用.
探索PSMA参与调节瘤微环境及其对治疗耐药性的影响.

主要方法:

文献综述侧重于PSMA的分子和生物功能.
整合有关PSMA酶活性,支架功能和监管机制的信息.
分析PSMA在瘤血管生成,免疫排除和 stromal激活中的作用.

主要成果:

PSMA将谷氨酸和单碳代谢与细胞增殖,氧化还原平衡和表观遗传调节联系起来.
通过与脚手架蛋白和克拉特林依赖性内细胞分裂的相互作用,PSMA充当分子信号枢纽.
在与瘤相关的内皮中,PSMA的表达促进了血管生成,并在各种恶性瘤中影响了瘤微环境.

结论:

PSMA是一种多方面的蛋白质,通过酶和非酶功能调节瘤生物学.
了解PSMA的分子机制对于解释临床异质性和设计改进的PSMA向干预措施至关重要.
作为瘤微环境的调节者,PSMA的作用为治疗策略提供了新的途径.

关键词:

在PSMA上,PSMA可以在PSMA上进行交易.在RLT中,RLT是指在RLT中使用RLT.在此之前,TME的治疗目标是治疗的目标.瘤血管新生发生.

更多相关视频

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...